Potential benefit of dolutegravir once daily: efficacy and safety

Alessandra Fantauzzi,1 Ombretta Turriziani,2 Ivano Mezzaroma11Department of Clinical Medicine, 2Department of Molecular Medicine, Sapienza, University of Rome, Rome, ItalyAbstract: The viral integrase enzyme has recently emerged as a primary alternative target to block HIV-1 replication, and integra...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Fantauzzi A, Turriziani O, Mezzaroma I
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://doaj.org/article/c84ab631ed7c4efe96beff0bea26b856
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!